This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pacira Pharmaceuticals Inc (PCRX)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -63.91M -52.28M -43.33M -27.15M
Operating Gains/Losses 3.43M 1.06M 273.00K 11.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -10.24M -2.24M -922.00K 264.00K
(Increase) Decrease in Inventories -3.48M -10.83M 360.00K 124.00K
(Increase) Decrease In Other Current Assets 0.00 0.00 14.00K 48.00K
(Decrease) Increase In Payables 10.24M 1.39M 2.55M -612.00K
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 -2.18M
(Increase) Decrease In Other Working Capital 31.00K -18.18M 1.09M 1.01M
Other Non-Cash Items 11.51M 4.78M 3.70M -652.00K
Net Cash From Continuing Operations -43.22M -70.13M -31.00M -24.88M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -43.22M -70.13M -31.00M -24.88M
Sale of Property, Plant & Equipment 0.00 1.00K 14.00K 1.00K
Cash Used for Investing Activities
Sale of Short-Term Investments 85.56M 53.12M 0.00 0.00
Purchases of Property, Plant & Equipment -12.79M -18.26M -6.17M -6.77M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -114.30M -54.05M -29.97M 0.00
Other Cash from Investing Activities -2.03M -10.34M 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -43.56M -29.52M -36.12M -6.77M
Issuance of Debt 120.00M 27.50M 0.00 7.50M
Cash Used for Financing Activities
Issuance of Capital Stock 3.86M 63.72M 87.16M 2.00K
Repayment of Long-Term Debt -27.50M -26.25M 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 -2.00K
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -7.19M -1.36M 0.00 43.20M
Net Cash From Financing Activities 89.16M 63.61M 87.16M 50.70M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 2.39M -36.04M 20.04M 19.06M

PCRX Pacira Pharmaceuticals Inc

Analysts Ratings for PCRX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 5 5 5 5
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

Brokerage Partners

PCRX Chatter

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs